Abstract:Local control is essential for radical cure of NSCLC. Previous studies have investigated the clinicopathological risk factors for locoregional recurrence (LR), but the genomic biomarkers associated with LR have been inadequately studied. This study investigates the molecular biomarkers associated with LR regardless of distant metastasis in NSCLC patients, which could help improve local control and potentially improve overall survival for NSCLC patients. Background Locoregional recurrence is of high risk and is associated with a poor prognosis in terms of OS for non‐small cell lung cancer (NSCLC). Local control is essential for radical cure of NSCLC. Previous studies have investigated the clinicopathological risk factors for locoregional recurrence, but the genomic biomarkers associated with locoregional recurrence have been inadequately studied. Methods A total of 118 patients who underwent tumor resection with mutation‐detected tumor specimens were included. Tumor samples at surgery and pretreatment/postoperative blood samples were collected for mutational profiling. Results Among 48 patients with disease recurrence, 46% developed locoregional recurrence (LR) and 75% developed distant metastasis (DM). The 3‐year actuarial risk of LR and DM was 25% and 43%, respectively. The first sites of failure were locoregional only (29%), locoregional and distant (10%), and distant only (61%). Patients with LR showed significantly higher ctDNA level than those with only DM at the time of initial recurrence. On multivariate analysis of baseline risk factors, the presence of allele frequency heterogeneity and baseline ctDNA shedding were found to be independently associated with a higher risk of LR. Patients with disruptive TP53 mutations had significantly lower LR‐free survival as compared to patients with wild‐type TP53 or nondisruptive mutations. EGFR mutations showed a favorable prognostic value for LR and is not induced by EGFR tyrosine kinase inhibitor therapy. Both disruptive TP53 mutation and EGFR mutation remained the significant prognostic factor after adjustment for histological type, pathologic nodal stage and adjuvant therapy. Conclusions Nearly half of disease recurrences after surgery for NSCC involved locoregional sites. We identified genomic biomarkers from baseline tumor and ctDNA samples which showed promising prognostic value for LR only. This can help identify patients who had a higher risk of locoregional recurrence regardless of the risk of distant metastasis.

Risk of locoregional recurrence after breast cancer surgery by molecular subtype-a systematic review and network meta-analysis

Incidence and Risk Factors of Lymph Node Metastasis in Breast Cancer Patients Without Preoperative Chemoradiotherapy and Neoadjuvant Therapy: Analysis of SEER Data.

Locoregional Recurrence by Tumor Biology in Breast Cancer Patients after Preoperative Chemotherapy and Breast Conservation Treatment

Predictors for local invasive recurrence of ductal carcinoma in situ of the breast: a meta-analysis.

Biological subtype predicts locoregional recurrence after postmastectomy radiotherapy in Chinese breast cancer patients.

Predicting Locoregional Recurrence in Triple-Negative Breast Cancer Using Novel Molecular Subtyping.

Molecular subtype and risk of local recurrence after nipple‐sparing mastectomy for breast cancer

Factors Predicting Locoregional Recurrence After Neoadjuvant Chemotherapy and Nipple-Sparing/Skin-Sparing Mastectomy With Immediate Breast Reconstruction

A Single-Center Retrospective Analysis of Local and Distant Relapse of Breast Cancer Following Immediate Breast Reconstruction According to Molecular Subtypes

Spatiotemporal Patterns of Loco-Regional Recurrence After Breast-Conserving Surgery

Locoregional Recurrence Risk in Breast Cancer Patients with Estrogen Receptor Positive Tumors and Residual Nodal Disease following Neoadjuvant Chemotherapy and Mastectomy without Radiation Therapy

Risk Factors of Locoregional Relapse in Locally Advanced Breast Cancer Treated with Neoadjuvant Chemotherapy Following Mastectomy and Radiotherapy

Molecular risk factors for locoregional recurrence in resected non‐small cell lung cancer

Can a Subgroup at High Risk for LRR Be Identified from T1-2 Breast Cancer with Negative Lymph Nodes after Mastectomy? A Meta-Analysis

Risk Stratification Model for Prediction of Locoregional Recurrence in Patients with Pathologic T1-2N0 Breast Cancer after Mastectomy

Locoregional Recurrence Following Nipple-Sparing Mastectomy with Immediate Breast Reconstruction: Patterns and Prognostic Significance.

Locoregional Breast Cancer Recurrence in the European Organisation for Research and Treatment of Cancer 10041/BIG 03-04 MINDACT Trial: Analysis of Risk Factors Including the 70-Gene Signature

Effect of postmastectomy radiotherapy on pT1-2N1 breast cancer patients with different molecular subtypes

Outcomes Following Salvage Radiation and Systemic Therapy for Isolated Locoregional Recurrence of Breast Cancer after Mastectomy: Impact of Constructed Biologic Subtype

Locoregional recurrence and survival of breast−conserving surgery compared to mastectomy following neoadjuvant chemotherapy in operable breast cancer

67P Analysis of Local-Regional Recurrence in Young Women (≤ 35Y) Receiving Mastectomy for Operable Breast Cancer